Cargando…
Boosting NAD(+) for the prevention and treatment of liver cancer
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905329/ https://www.ncbi.nlm.nih.gov/pubmed/27308492 http://dx.doi.org/10.1080/23723556.2014.1001199 |
_version_ | 1782437248849936384 |
---|---|
author | Djouder, Nabil |
author_facet | Djouder, Nabil |
author_sort | Djouder, Nabil |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC. |
format | Online Article Text |
id | pubmed-4905329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49053292016-06-15 Boosting NAD(+) for the prevention and treatment of liver cancer Djouder, Nabil Mol Cell Oncol Commentary Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC. Taylor & Francis 2015-02-03 /pmc/articles/PMC4905329/ /pubmed/27308492 http://dx.doi.org/10.1080/23723556.2014.1001199 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Commentary Djouder, Nabil Boosting NAD(+) for the prevention and treatment of liver cancer |
title | Boosting NAD(+) for the prevention and treatment of liver cancer |
title_full | Boosting NAD(+) for the prevention and treatment of liver cancer |
title_fullStr | Boosting NAD(+) for the prevention and treatment of liver cancer |
title_full_unstemmed | Boosting NAD(+) for the prevention and treatment of liver cancer |
title_short | Boosting NAD(+) for the prevention and treatment of liver cancer |
title_sort | boosting nad(+) for the prevention and treatment of liver cancer |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905329/ https://www.ncbi.nlm.nih.gov/pubmed/27308492 http://dx.doi.org/10.1080/23723556.2014.1001199 |
work_keys_str_mv | AT djoudernabil boostingnadforthepreventionandtreatmentoflivercancer |